<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147987">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897987</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CR-009-FU</org_study_id>
    <nct_id>NCT01897987</nct_id>
  </id_info>
  <brief_title>Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial</brief_title>
  <official_title>Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipost Co Ltd.</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM®
      versus placebo, for the treatment of BPD in premature infants. Subjects who participated in
      and completed the initial stage of the Phase II trial (NCT01297205 ) will be followed-up
      until 60 months of corrected age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who completed the initial stage of the Phase II clinical trial will be followed-up
      at 7 additional visits: corrected age of 6, 12,18, 24, 36, 48, and 60 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infection</measure>
    <time_frame>6, 12, 18, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)</measure>
    <time_frame>6, 12, 18, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of admissions to Emergency Room</measure>
    <time_frame>6, 12, 18, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total number of admissions to Emergency Room and number of admissions to Emergency Room due to resiratory problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6, 12, 18, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth measured by Z-score</measure>
    <time_frame>6, 12, 18, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy</measure>
    <time_frame>24 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deafness or Blindness</measure>
    <time_frame>24 months, corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>6, 12, 24,36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes in vital signs</measure>
    <time_frame>6, 12, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes in physical exam</measure>
    <time_frame>6, 12, 24, 36, 48, and 60 months, corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Pneumostem®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single intratracheal administration of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumostem®</intervention_name>
    <arm_group_label>Pneumostem®</arm_group_label>
    <other_name>Human umbilical cord blood-derived mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <arm_group_label>normal saline</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who completed the safety and efficacy evaluations in Pneumostem Phase II
             clinical trial

          -  Subject  with a written consent form signed by a legal representative or a parent
             upon explanation of the clinical trial

        Exclusion Criteria:

          -  Subject whose parent or legal representative does not agree to participate in the
             study

          -  subject who is considered inappropriate to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Months</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonsoon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ai-Rhan Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neonatology, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wonil Oh, MD, PhD</last_name>
    <phone>+82-2-3465-6670</phone>
    <email>wioh@medi-post.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ai-Rhan Kim, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0002T1G&amp;selectaction=View&amp;uid=U0000NAG&amp;ts=116&amp;cx=51y1dz</url>
    <description>Pneumostem- Phase I</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Blood Derived Mesenchymal Stem Cells</keyword>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>Premature infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
